WriteResult Digital Pen Selected for Hepatitis C ePRO Study

Share Article

2011 Closes out as Record Year for Study Start-ups

“We are excited to be part of such an important study, and we feel our patient-focused ePRO solution is especially well suited to gathering the voice of the patients affected by Liver Disease”.

WriteResult announced today it is receiving data from the first randomized patients in a new Phase III clinical study for the treatment of Hepatitis C. This marked the company’s seventh study started in 2011, a record year for portfolio growth.

“We are excited to be part of such an important study, and we feel our patient-focused ePRO solution is especially well suited to gathering the voice of the patients affected by Liver Disease”.

Hepatitis C is a ‘silent’ virus that can lead to liver cirrhoses and life-threatening complications. It is estimated there are 170 million people chronically infected with Hepatitis C worldwide [1]. The writeresult digital pen ePRO solution is an easy and efficient way to capture the patient perspective of treatments for this disease and others like it.

In addition to this new disease area, WriteResult has extensive experience in Patient Reported Outcomes for studies in Dermatology, Rheumatology, Inflammatory Disease and Pain. A special focus of the writeresult team is ePRO in Phase II and Phase III studies targeting approval by regulatory authorities.

About WriteResult

WriteResult offers full-service data management solutions for clinical research through the collection and verification of ePROs leveraging digital pen and paper technology. Since 2006 WriteResult has partnered with study sponsors to deliver a simple and effective ePRO solution — rapid study startup with clean, real-time data using a technology that’s intuitive for sites and patients.

For more information about WriteResult, please email solutions(at)writeresult(dot)com or call (908) 272-4787.

References
[1] World Hepatitis Alliance, http://www.worldhepatitisalliance.org, Last accessed February 2012

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Francesca Heintz
Visit website